Skip to content
TrialScanner

NCT03533257

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

Phase 2CompletedAMLXLead

Registry record

Lead sponsor
Amylyx Pharmaceuticals Inc.
Conditions
Alzheimer Disease
Primary completion
Oct 22, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03533257 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03533257: Study to Assess the Safety... | TrialScanner